Clinical Trial Update: Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on an antioxidant and NMDA receptor blocker for anoxic brain injury after cardiac arrest.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Arrest

Drugs mentioned

• Antioxidant and NMDA receptor blocker

Snippet

Sponsor: GNT Pharma | Conditions: Cardiac Arrest | Phase 2 | Status: UNKNOWN